Prague, Czechia

Jiri Kolinsky

This inventor holds 2 USPTO granted patents. Top assignees: Spofa, Spojene Podniky Pro Zdratvonickou Vyrobu, Spofa, Spojene Podniky Pro Zdravotnickou Vyrobu. Active years: 1985.


% Patents Active = 100.0

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1985

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jiri Kolinsky: Innovator in Immunostimulatory Compounds

Introduction

Jiri Kolinsky is a notable inventor based in Prague, Czech Republic. He has made significant contributions to the field of immunology through his innovative inventions. With a total of 2 patents, Kolinsky has focused on developing compounds that exhibit unique biological activities.

Latest Patents

Kolinsky's latest patents include the invention of L-Alanyl-D-isoglutamine adamantylamide. This compound is characterized by its immunostimulatory and immunoadjuvant activity, demonstrating an unusual degree of effectiveness without relevant side effects such as pyrogenity. Another significant patent involves luteinizing and follicle stimulating hormones, which are described as having high gonadotropic activity. These hormones are valuable in both human and veterinary medicine.

Career Highlights

Throughout his career, Jiri Kolinsky has worked with several prominent companies, including Spofa and Spojene Podniky Pro Zdravotnickou Vyrobu. His work in these organizations has contributed to advancements in medical and pharmaceutical research.

Collaborations

Kolinsky has collaborated with notable coworkers such as Martin Flegel and Milan Krojidlo. Their joint efforts have furthered the development of innovative solutions in the field of health and medicine.

Conclusion

Jiri Kolinsky's contributions to immunology through his patents and collaborations highlight his role as a significant innovator in the field. His work continues to impact both human and veterinary medicine positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…